حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Lifecore Biomedical Inc.
LFCRLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. Address: 3515 Lyman Boulevard, Chaska, MN, United States, 55318
Analytics
سعر الهدف في وول ستريت
7 USDنسبة السعر إلى الأرباح
51.8462العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية LFCR
تحليلات الأرباح LFCR
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح LFCR
تقييم الأسهم LFCR
المالية LFCR
نتائج | 2019 | ديناميات |